

Product Name: Zanamivir Revision Date: 01/10/2021

Product Data Sheet

Zanamivir

	Blow	
Cat. No.:	B2136	NH ₂
CAS No.:	139110-80-8	N NH2
Formula:	C12H20N4O7	HN/
M.Wt:	332.31	
Synonyms:		НО
Target:	Microbiology & Virology	Вн 0
Pathway:	NA	
Storage:	Store at -20°C	
	810	810
Solvent & Solubility		
		and the second se

	insoluble in DMSO; ir	insoluble in DMSO; insoluble in EtOH; \geq 8.99 mg/mL in H2O				
In Vitro	Preparing Stock Solutions	Mass Solvent Concentration	1mg	5mg	10mg	
		1 mM	3.0092 mL	15.0462 mL	30.0924 mL	
		5 mM	0.6018 mL	3.0092 mL	6.0185 mL	
		10 mM	0.3009 mL	1.5046 mL	3.0092 mL	

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary

Influenza A/B virus neuraminidases inhibitor

IC₅₀ & Target

In Vitro

Cell Viability Assay	and the second
Cell Line:	HeLa-CD4-LTR-βgal cells and HeLa-tat cell, CV-1 cell
Preparation method:	The solubility of this compound in DMSO is >16.6mg/mL. General tips for
	obtaining a higher concentration: Please warm the tube at 37 $^\circ C$ for 10 minutes
	and/or shake it in the ultrasonic bath for a while. Stock solution can be stored
	below -20°C for several months.
Reacting conditions:	5 nM-10 mM
	• 1 · · · · · · · · · · · · · · · · · ·

1 www.apexbt.com

	Applications:	In HeLa-CD4-LTR-βgal cells, zananivir interfered with cell-cell fusion with the		
		IC50 of 0.19 mM. In CV-1 cell monolayers, zananivir (0.5 mM) reduced plaque		
		area by 97%. Zananivir caused a concentration-dependent inhibition of		
		hemadsorption. Zananivir (5 mM) strikingly reduced lipid mixing. zanamivir		
		suppressed the growth of influenza A and B viruses with IC50 values of 5		
	210	nM-14 nM for laboratory-passaged strains and from 20 nM-16 μM for clinical		
	CEL	isolates.		
	Animal experiment			
	Animal models:	Mice infected with influenza A		
	Dosage form:	Intranasal, 0.01-4 mg/kg		
	Applications:	Intranasal zananivir treatment given prophylactically plus twice daily over days		
In Vivo		0 to 3 in mice infected with influenza A reduced mortality and viral titres in lung		
		homogenated and improved lung consolidation scores over 10 days.		
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may		
	BIO	slightly differ with the theoretical value. This is caused by an experimental		
	PERMIT	system error and it is normal.		
		and the second se		

Product Citations

See more customer validations on www.apexbt.com.

References



 Greengard O, Poltoratskaia N, Leikina E, et al. The anti-influenza virus agent 4-GU-DANA (zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA[J]. Journal of virology, 2000, 74(23): 11108-11114.
Elliott M. Zanamivir: from drug design to the clinic[J]. Philosophical Transactions of the Royal Society of London. Series B, 2001, 356(1416): 1885.

Caution



FOR RESEARCH PURPOSES ONLY. NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.













